Xue Bao

Dr. Xue Bao


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2018 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
XBXue Bao
Xue Bao
XBXue Bao
Xue Bao
LJLinda Johnson
Linda Johnson
IMIram Faqir Muhammad
Iram Faqir Muhammad
MPMargaretha Persson
Margaretha Persson
GEGunnar Engström
Gunnar Engström
Chronic low-grade inflammation and associated insulin resistance and metabolic abnormalities have been proposed as ‘common soil’ for diabetes mellitus (DM) and cardiovascular disease (CVD). This paper aimed to investigate the inflammatory profiles of DM and CVD and to distinguish their shared and specific markers. Based on the Malmö Diet and Cancer cohort, total and differential leukocyte counts were measured in 25,969 participants without previous DM or CVD and were studied in relation to incident DM (mean follow-up 17.4 ± 5.58 years) and incident CVD (i.e., coronary events, including fatal and nonfatal myocardial infarction, or stroke); mean follow-up 17.7 ± 5.46 years, using multivariable Cox regression models. Furthermore, plasma concentrations of another seven inflammatory markers were examined in relation to incident DM and incident CVD in a sub-cohort of 4658 participants. The associations of each inflammatory marker with incident DM versus incident CVD were compared using the Lunn–McNeil competing risks approach. In sensitivity analyses, those who developed both DM and CVD during follow-up were excluded. After adjustment for conventional risk factors, total and differential leukocyte counts, orosomucoid, and C-reactive protein were associated with an increased risk of both DM and CVD. Neutrophil to lymphocyte ratio, ceruloplasmin, alpha1-antitrypsin and soluble urokinase plasminogen activator receptor predicted increased risk of CVD but not DM, while haptoglobin and complement C3 showed the opposite pattern. In competing risks analyses, lymphocyte count and complement C3 had stronger associations with risk of DM than with risk of CVD (p for equal associations = 0.020 and 0.006). The reverse was true for neutrophil to lymphocyte ratio (p for equal associations = 0.025). Results were consistent in sensitivity analyses. The results indicated substantial similarities in the inflammatory profiles associated with DM and CVD. However, there are also significant differences. These findings may help discriminate between individuals at elevated risk of DM and those at elevated risk of CVD, which is a prerequisite for targeted therapies.

8 December 2023 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Open access
PDF file
YTYing Tan
Ying Tan
XBXue Bao
Xue Bao
YLYuyu Li
Yuyu Li
GSGuo Song
Guo Song
HLHe Lu
He Lu
BXBiao Xu
Biao Xu
Purpose: Complete and rapid recanalization of blood flow by percutaneous coronary intervention (PCI) is the most effective intervention for patients with ST-segment elevation myocardial infarction (STEMI). However, myocardial ischemia/reperfusion (I/R) injury leads to microvascular obstruction (MVO), limiting its efficacy. Colchicine can reduce myocardial I/R injury, but its effect on MVO is unclear. Hence, this study aimed to assess the role and mechanism of colchicine on MVO. Methods: Clinical data on STEMI patients with PCI were collected and risk factors related to MVO were analyzed. The rat myocardial I/R model was established to evaluate the MVO by thioflavin S staining. The myocardial I/R model of mice was treated with PBS or colchicine at the reperfusion. The effect of colchicine on cardiomyocyte apoptosis after I/R was evaluated by TUNEL and expression of cleaved caspase-3. ROS levels were detected in H9c2 cells to evaluate the colchicine effect on myocardial oxidative stress. Moreover, the mechanism through which colchicine attenuated MVO was examined using flow cytometry, WB, ELISA, immunohistochemistry, bioinformatics analysis, and immunofluorescence. Results: Multivariate analysis showed that elevated neutrophils were associated with extensive MVO. Colchicine could attenuate MVO and reduce neutrophil recruitment and NETs formation after myocardial I/R. In addition, colchicine inhibited cardiomyocyte apoptosis in vivo and ROS levels in vitro. Furthermore, colchicine inhibited neutrophil proliferation in the bone marrow (BM) by inhibiting the S100A8/A9 inflammatory signaling pathway. Conclusions: Colchicine attenuated MVO after myocardial I/R injury by inhibiting the proliferation of neutrophils in BM through the neutrophil-derived S100A8/A9 inflammatory signaling pathway.

22 November 2023 in International Journal of Cardiology
Verified
Journal Article
Closed access
NPNingxin Peng
Ningxin Peng
LGLiqiong Guo
Liqiong Guo
ZWZhonghai Wei
Zhonghai Wei
XWXiao Wang
Xiao Wang
LZLei Zhao
Lei Zhao
XBXue Bao
Xue Bao

26 September 2020 in Cardiology Research and Practice
Verified
Journal Article
Open access
HWHan Wu
Han Wu
RLRan Li
Ran Li
KWKun Wang
Kun Wang
DMDan Mu
Dan Mu
JCJian-Zhou Chen
Jian-Zhou Chen
BXBiao Xu
Biao Xu
Background. The relationship between fasting blood glucose (FBG) and microvascular obstruction (MVO) after primary percutaneous coronary intervention (PCI) remains unclear in nondiabetic patients with ST-segment elevation myocardial infarction (STEMI). This study aimed to determine the predictive value of FBG in MVO in nondiabetic STEMI patients. Methods. A total of 108 nondiabetic STEMI patients undergoing primary PCI were enrolled in this study. The patients were classified into either the MVO group or non-MVO group based on cardiac magnetic resonance imaging (CMR). Results. FBG in the MVO group was higher than in the non-MVO group. Univariate analysis showed that FBG, peak high-sensitive troponin T (TnT), pre-PCI thrombolysis in myocardial infarction (pre-PCI TIMI) flow, left ventricular ejection fraction (LVEF), infarction size, left ventricular end-diastolic diameter (LVEDd), left ventricular end-diastolic volume (LVEDV), and global longitudinal strain (GLS) were likely predictive factors of MVO. After adjustment for other parameters, FBG, peak TnT, LVEF, and LVEDV remained independent predictors for MVO. Conclusion. FBG was independently associated with MVO in nondiabetic STEMI patients.

12 October 2024 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
YWYi Wang
Yi Wang
XLXiaoli Liu
Xiaoli Liu
BWBaochuan Wu
Baochuan Wu
XTXi Tan
Xi Tan
LCLin Chen
Lin Chen
RGRong Gu
Rong Gu
Among heart failure patients with obesity, the prognosis is better than those with normal weight, a phenomenon known as the obesity paradox. However, it is unclear whether lipoprotein levels play a mediating role in the machine of the obesity paradox. The study included 1663 heart failure patients hospitalized from January, 2019 through August, 2022. Kaplan-Meier survival analysis and Log-rank tests were performed for three endpoints in order to determine cumulative event-free survival. We investigated the correlation between Body Max Index (BMI) and outcomes by multifactorial Cox models. Mediation analysis was applied to study the presence and magnitude of mediation effects of triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, apolipoprotein A1 and apolipoprotein B, with the association between BMI and endpoints. In MACCEs, the median follow-up period was 679 days. In Cox model, compared with the underweight group, a high BMI level was significantly associated with lower all-cause mortality (HR=0.47, 95%CI 0.31~0.69, p<0.001, obese vs underweight), cardiovascular mortality (HR=0.46, 95%CI 0.30~0.73, p<0.001, obese vs underweight) and the incidence of MACCEs (HR=0.68, 95%CI 0.53~0.88, p=0.003, obese vs underweight). Mediation analysis revealed that TG was the strongest mediator between BMI and endpoints, with proportions of mediated effects of 6.6% (95%CI 2.2%~18.0%, p=0.0258, in all-cause death),7.0% (95%CI 2.3%~18.9%, p=0.0301, in cardiovascular death) and 10.2% (95%CI 3.3%~27.4%, p=0.0185, in MACCEs). There is an "obesity paradox" in patients with heart failure, and lipoprotein levels especially triglyceride mediate the association between BMI and cardiovascular outcomes.

16 June 2025 in Clinical Cardiology
Verified
Journal Article
Open access
XLXiaoli Liu
Xiaoli Liu
HCHeyu Chu
Heyu Chu
GSGuo Song
Guo Song
YWYi Wang
Yi Wang
JDJunfeng Duan
Junfeng Duan
RGRong Gu
Rong Gu
Aims: High plasma fibrinogen and systemic inflammation response index (F‐SIRI) has been proposed as a novel prognostic factor in resectable gastric cancer. However, available data on the prognostic value of F‐SIRI in chronic heart failure (CHF) patients is limited. We aimed to conduct a retrospective cohort study exploring the correlation between F‐SIRI and prognosis in CHF individuals. Methods: We consecutively enrolled 1589 hospitalized patients (aged 66 ± 8 years, 32.9% women) with CHF from January 1, 2019 to August 31, 2022 in this single‐center retrospective study. SIRI was calculated with the formula (monocyte count*neutrophil count/lymphocyte count). The primary endpoints encompassed all‐cause death, the major adverse cardiac and cerebral events (MACCEs) and cardiovascular death. The association between F‐SIRI and the risk of developing adverse outcomes were explored using four multivariate‐adjusted Cox proportional hazard models. Results: During a median follow‐up of 687 days, 207 all‐cause deaths, 462 MACCEs and 136 cardiovascular deaths were recorded. After adjusting for potential confounding factors, only risk of all‐cause death remained significantly associated with higher levels of F‐SIRI. The hazard ratios (HRs) for the highest F‐SIRI group (F‐SIRI = 2) versus the lowest F‐SIRI group (F‐SIRI = 0) were 2.37 (95% confidence interval [CI], 1.46−3.83; p < 0.001) for all‐cause death. The addition of F‐SIRI could increase the prognostic ability for all‐cause death on the basis of traditional risk factors. Conclusions: F‐SIRI is a significant predictor of all‐cause death but has limited predictive value for MACCEs and cardiovascular death in CHF patients.